IL-17 Inhibition: A Targeted Approach to the Management of Psoriatic Arthritis

Download All
This program, which includes a CME-certified interactive video module, downloadable slides, and a ClinicalThought commentary, provides expert perspectives on approved and investigational IL-17–targeted therapies for treating psoriatic arthritis.
Dafna D. Gladman, MD, FRCPC
Arthur Kavanaugh, MD

IL-17 Inhibition: A Targeted Approach to the Management of Psoriatic Arthritis

In this downloadable slideset, Dafna D. Gladman, MD, FRCPC, reviews the role of IL-17A in psoriatic arthritis and examines key data surrounding the use of IL-17–targeted therapies to treat this condition.

Released: October 7, 2016

In this interactive, CME-certified video module, Dafna D. Gladman, MD, FRCPC, provides expert perspectives on approved and investigational IL-17–targeted therapies for treating psoriatic arthritis.

Dafna D. Gladman, MD, FRCPC Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 7, 2016 Expired: No longer available for credit

ClinicalThought

The 2016 American College of Rheumatology annual meeting gave us promising data on agents targeting IL-17 in psoriatic arthritis. Here’s my take on select abstracts.

Arthur Kavanaugh, MD Released: February 1, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings